Company news

Unicycive Therapeutics, Inc. news in 2023

Unicycive Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Unicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) in Patients with Chronic Kidney Disease on Dialysis

December 17, 2023

Unicycive Therapeutics to Participate in Two Investor Conferences in December 2023

November 28, 2023

Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update

November 13, 2023

Unicycive Therapeutics Reaches Alignment with the FDA on Path to File New Drug Application for Oxylanthanum Carbonate (OLC)

October 22, 2023

Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD

September 5, 2023

Unicycive Therapeutics Featured on Nasdaq Amplify Issuer Spotlight Series

August 28, 2023

Unicycive Announces Second Quarter 2023 Financial Results and Provides Business Update

August 13, 2023

Unicycive Therapeutics to Participate in the H.C. Wainwright 2nd Annual Kidney Conference

July 19, 2023

Unicycive Therapeutics Announces Publication of Positive Comparison of Oxylanthanum Carbonate to Commercially Available Phosphate Binders in the American Journal of Nephrology

July 17, 2023

Unicycive Therapeutics Provides Regulatory Update on Lanthanum Dioxycarbonate Program

June 28, 2023

Unicycive to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9: 00 A.M. ET

June 15, 2023

Unicycive Announces First Quarter 2023 Financial Results and Provides Business Update

May 15, 2023

Unicycive Announces Acceptance of Multiple Datasets to Be Presented at the European Renal Association Congress

April 23, 2023

Unicycive Announces Full Year 2022 Financial Results and Provides Business Update

March 30, 2023

Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb

March 5, 2023

Unicycive to Highlight Potential of UNI-494 to Restore Mitochondrial Function and Reduce Oxidative Stress at Two Upcoming Medical and Scientific Meetings

February 26, 2023

Unicycive Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of Korea

February 1, 2023

Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation’s Spring Clinical Meetings

January 22, 2023

Unicycive Announces Acceptance of Four Abstracts for Presentation at the World Congress of Nephrology 2023

January 4, 2023